Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

NKAIN1 predicts poor prognosis and associated with drug resistance and immune infiltration in prostate adenocarcinoma

Xuancai Chen, Cong Wang, Xingyao Qu, Jixiang Wu, Zongming Jia, Siyu Wang, Can Hu, Wentao Yao, Tong Zhang, Ying Kong, Yuhua Huang

BMC Cancer · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background Na, K-ATPase interaction 1 (NKAIN1) is a transmembrane protein that can interact with Na, K-ATPase β1 subunit. NKAIN1 has prognostic value in several cancers, but its biomarker and carcinogenic roles in the development of prostate adenocarcinoma (PRAD) remain underexplored. Methods The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database were used to analyze the expression and prognostic significance of NKAIN1 in PRAD. The Genomics of Drug Sensitivity in Cancer (GDSC) database and The Cancer Therapeutics Response Portal (CTRP) database were used to analyze drug resistance. Single-cell RNA sequencing was employed to define cell clusters. GO, KEGG, and GSEA enrichment analyses were performed to predict the function of NKAIN1-related factors. Finally, CCK8, Colony formation assay, transwell experiments, and subcutaneous tumor formation in nude mice were conducted to validate the role of NKAIN1 in PRAD development. Results NKAIN1 was significantly upregulated in PRAD, correlating with advanced TNM stages, poor survival, and may be involved in drug resistance. High NKAIN1 expression was associated with altered immune infiltration. Additionally, NKAIN-related genes were enriched in Wnt signaling, metabolism, and immune-related pathways. Knockdown of NKAIN1 suppressed PRAD cell proliferation, migration, invasion, and immune evasion in vitro and tumor growth in vivo. Conclusion NKAIN1 serves as a prognostic, drug resistance, and immune infiltration marker. Moreover, NKAIN1 promotes PRAD progression and suggests it acts as a potential therapeutic target. Trial registration This research has been retrospectively registered in the Ethics Committee institutional of the First Affiliated Hospital of Soochow University with the number of 2025–733.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Xuancai Chen, Cong Wang, Xingyao Qu, Jixiang Wu, Zongming Jia, Siyu Wang, Can Hu, Wentao Yao, Tong Zhang, Ying Kong, Yuhua Huang
Quelle
BMC Cancer
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
1471-2407
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Xuancai Chen, Cong Wang, Xingyao Qu, Jixiang Wu, Zongming Jia, Siyu Wang, Can Hu, Wentao Yao, Tong Zhang, Ying Kong, Yuhua Huang (2026). NKAIN1 predicts poor prognosis and associated with drug resistance and immune infiltration in prostate adenocarcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-16835-0
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1